Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

PEN

Penumbra Inc

Mar 13 • 12:01PM ET

258.55

Dollar change -8.58
Percentage change -3.21	%

Healthcare • Medical Devices • USA • NYSE

Peers: BSX ISRG EW HOLX MDT JNJ ABT SYK ZBH TFX

| Held by: IJH VTI VB VXF VBK MDY IWP IHI SPMD IJK

Index	-	P/E	751.59	EPS (ttm)	0.34	Insider Own	3.46%	Shs Outstand	38.49M	Perf Week	-6.89%
Market Cap	9.96B	Forward P/E	52.47	EPS next Y	4.93	Insider Trans	-10.05%	Shs Float	37.18M	Perf Month	-3.63%
Income	14.01M	PEG	18.59	EPS next Q	0.67	Inst Own	91.13%	Short Float	3.65%	Perf Quarter	7.34%
Sales	1.19B	P/S	8.34	EPS this Y	64.87%	Inst Trans	-1.13%	Short Ratio	2.89	Perf Half Y	26.66%
Book/sh	29.90	P/B	8.65	EPS next Y	34.64%	ROA	0.91%	Short Interest	1.36M	Perf Year	7.01%
Cash/sh	8.83	P/C	29.28	EPS next 5Y	40.42%	ROE	1.20%	52W Range	148.00 - 310.00	Perf YTD	8.87%
Dividend Est.	-	P/FCF	67.61	EPS past 5Y	-23.21%	ROI	1.03%	52W High	-16.60%	Beta	0.56
Dividend TTM	-	Quick Ratio	3.44	Sales past 5Y	17.38%	Gross Margin	62.77%	52W Low	74.69%	ATR (14)	10.47
Dividend Ex-Date	-	Current Ratio	6.01	EPS Y/Y TTM	-84.18%	Oper. Margin	7.22%	RSI (14)	40.92	Volatility	4.32% 3.84%
Employees	4500	Debt/Eq	0.19	Sales Y/Y TTM	12.86%	Profit Margin	1.17%	Recom	1.70	Target Price	307.71
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	-37.47%	Payout	0.00%	Rel Volume	0.40	Prev Close	267.13
Sales Surprise	3.17%	EPS Surprise	8.23%	Sales Q/Q	10.83%	Earnings	Feb 18 AMC	Avg Volume	469.77K	Price	258.55
SMA20	-7.54%	SMA50	-3.45%	SMA200	17.49%	Trades		Volume	79,341	Change	-3.21%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-21-25	Initiated	UBS	Buy	$305
Dec-17-24	Initiated	Oppenheimer	Outperform	$275
Dec-11-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$190 → $275
Sep-18-24	Initiated	Stifel	Buy	$238
Sep-03-24	Initiated	Leerink Partners	Outperform	$263
Jul-31-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$289 → $150
Jul-31-24	Downgrade	Citigroup	Buy → Neutral	$165 → $178
Feb-23-24	Downgrade	JP Morgan	Overweight → Neutral	$284 → $250
Sep-06-23	Initiated	Morgan Stanley	Equal-Weight	$265
Jul-19-23	Initiated	Robert W. Baird	Outperform	$375
Mar-29-23	Downgrade	Needham	Buy → Hold
Jan-30-23	Initiated	Piper Sandler	Overweight	$275
Nov-04-22	Upgrade	Citigroup	Neutral → Buy	$217 → $212
Oct-12-22	Initiated	Jefferies	Buy	$230
Oct-05-22	Downgrade	Citigroup	Buy → Neutral	$170 → $217
Sep-09-22	Upgrade	Needham	Hold → Buy
Jul-18-22	Initiated	RBC Capital Mkts	Outperform	$195
Apr-19-22	Initiated	Deutsche Bank	Buy	$250
Mar-08-22	Initiated	Needham	Hold
Sep-16-21	Initiated	Truist	Buy	$350

Show Previous Ratings

Mar-04-25 03:04PM	Alcon Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Feb-28-25 08:01AM	3 Mid-Cap Stocks in Hot Water (StockStory)
Feb-21-25 04:05PM	Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors (PR Newswire)
Feb-20-25 12:00PM	Penumbra (PEN) Upgraded to Buy: Here's Why (Zacks)
Feb-19-25 04:41PM	Profit Machine Penumbra Surges On Solid Fourth-Quarter Beat, But Guidance Lags (Investor's Business Daily) +12.03%
01:45PM	Loading…
01:45PM	Why Penumbra (PEN) Stock Is Trading Up Today (StockStory)
07:46AM	Q4 2024 Penumbra Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	Penumbra Inc (PEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid International ... (GuruFocus.com)
Feb-18-25 06:00PM	Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings (Zacks)
05:20PM	Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:17PM	Penumbra: Q4 Earnings Snapshot (Associated Press Finance)
04:16PM	Penumbras (NYSE:PEN) Q4 Sales Beat Estimates (StockStory)
04:05PM	Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-17-25 08:06AM	Penumbra (PEN) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
Feb-14-25 04:04AM	Artivion (NYSE:AORT) Q3 Earnings: Leading The Medical Devices & Supplies - Cardiology, Neurology, Vascular Pack (StockStory)
04:01AM	Loading…
04:01AM	Unpacking Q3 Earnings: ICU Medical (NASDAQ:ICUI) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks (StockStory)
Feb-13-25 04:02AM	Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q3 (StockStory)
04:01AM	Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Merit Medical Systems (NASDAQ:MMSI) Vs The Rest (StockStory)
Jan-21-25 04:30PM	Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025 (PR Newswire)
Jan-16-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN) (Zacks)
Jan-08-25 05:06AM	Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
Dec-30-24 04:30PM	Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-25-24 12:45PM	Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think 'Yes' (Zacks)
Dec-23-24 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
Dec-19-24 07:37AM	Penumbra price target raised to $285 from $240 at Truist (TipRanks)
Dec-09-24 12:45PM	Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Dec-06-24 09:45AM	Why Penumbra (PEN) is a Top Growth Stock for the Long-Term (Zacks)
Nov-29-24 11:31AM	Why Is Penumbra (PEN) Up 6.7% Since Last Earnings Report? (Zacks)
Nov-25-24 05:05PM	Penumbra, Inc. (PEN): Innovating in Thrombectomy and Embolization with New FDA-Approved Technologies (Insider Monkey)
Nov-21-24 12:45PM	3 Reasons Growth Investors Will Love Penumbra (PEN) (Zacks)
04:30PM	Loading…
Nov-20-24 04:30PM	Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-18-24 10:00AM	Inside a $400 billion bet on the brain-computer interface revolution (Yahoo Finance)
Nov-17-24 04:50PM	Penumbra, Inc. (PEN): A Bull Case Theory (Insider Monkey)
Nov-06-24 12:29PM	Penumbra reveals positive data for algorithm-assisted thrombectomy tech (Clinical Trials Arena)
Nov-05-24 12:45PM	Here is Why Growth Investors Should Buy Penumbra (PEN) Now (Zacks)
09:50AM	Here's Why Penumbra (PEN) is a Strong Momentum Stock (Zacks)
09:00AM	New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options (PR Newswire)
Nov-04-24 11:19AM	Implied Volatility Surging for Penumbra (PEN) Stock Options (Zacks)
Oct-31-24 03:15AM	Penumbra Inc (PEN) Q3 2024 Earnings Call Highlights: Strong U.S. ... (GuruFocus.com) +8.32%
Oct-30-24 06:30PM	Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:30PM	Penumbra (PEN) Q3 Earnings and Revenues Top Estimates (Zacks)
04:24PM	Penumbra: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-23-24 10:02AM	Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-15-24 10:31AM	Penumbra completes enrolment for THUNDER study to treat ischemic stroke (Medical Device Network)
Oct-14-24 06:20PM	Why Penumbra Stock Zoomed 4% Higher Today (Motley Fool)
09:00AM	Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke (PR Newswire)
Oct-10-24 09:00AM	Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism (PR Newswire)
Oct-09-24 07:50AM	Penumbra price target raised to $222 from $205 at RBC Capital (TipRanks)
Oct-02-24 04:30PM	Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024 (PR Newswire)
Sep-18-24 06:29PM	Why Penumbra Stock Zoomed Nearly 5% Higher Today (Motley Fool)
Sep-16-24 06:53AM	Penumbra secures CE mark for CAVT technologies in Europe (Medical Device Network)
03:00AM	Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash 2.0 and Lightning Bolt 7 - in Europe (PR Newswire)
Sep-06-24 01:49AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)
01:49AM	Insider Sale: Director Harpreet Grewal Sells Shares of Penumbra Inc (PEN) (GuruFocus.com)
Aug-29-24 11:31AM	Why Is Penumbra (PEN) Up 20% Since Last Earnings Report? (Zacks)
06:55AM	Penumbra axes virtual reality division, will lay off 71 people (MedTech Dive)
Aug-27-24 04:30PM	Penumbra, Inc. to Present at the Baird Global Healthcare Conference (PR Newswire)
Aug-21-24 04:30PM	Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference (PR Newswire)
08:03AM	Penumbra sees 85.5% limb salvage rate in thrombectomy device trial (Medical Device Network)
Aug-16-24 01:01AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)
Aug-13-24 07:00AM	Penumbra, Inc. Announces $200 Million Share Repurchase Authorization (PR Newswire) +10.75%
Aug-02-24 04:30PM	Penumbra, Inc. to Present at the Canaccord Genuity Growth Conference (PR Newswire)
Jul-31-24 01:50PM	Q2 2024 Penumbra Inc Earnings Call (Thomson Reuters StreetEvents)
10:03AM	Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View (Zacks)
Jul-30-24 08:56PM	PEN Stock Earnings: Penumbra Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
07:00PM	Penumbra (PEN) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:30PM	Penumbra (PEN) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:32PM	Penumbra: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-23-24 10:01AM	Penumbra (PEN) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-18-24 04:39AM	Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock? (Zacks) -6.11%
Jul-17-24 12:45PM	Looking for a Growth Stock? 3 Reasons Why Penumbra (PEN) is a Solid Choice (Zacks)
Jul-04-24 03:30AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)
Jul-02-24 04:05PM	Penumbra, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for July 30, 2024 (PR Newswire)
Jun-13-24 09:45AM	Why Penumbra (PEN) is a Top Growth Stock for the Long-Term (Zacks)
Jun-06-24 11:31AM	Why Is Penumbra (PEN) Down 4.8% Since Last Earnings Report? (Zacks)
Jun-04-24 04:30PM	Penumbra, Inc. to Present at the Truist Securities MedTech Conference (PR Newswire)
May-23-24 04:30PM	Penumbra, Inc. to Present at the William Blair Growth Stock Conference (PR Newswire)
May-16-24 03:22AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells 600 Shares of Penumbra ... (GuruFocus.com)
May-15-24 07:41AM	Inari Medical (NARI) Fell on Investor Concerns (Insider Monkey)
May-13-24 12:08PM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 01:42PM	Penumbra, Inc. (NYSE:PEN) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:43AM	Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand (Zacks)
May-07-24 05:35PM	Penumbra Inc (PEN) Surpasses Analyst Revenue Forecasts in Q1 2024 (GuruFocus.com)
04:42PM	Penumbra: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports First Quarter 2024 Financial Results (PR Newswire)
May-01-24 04:05PM	Penumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference (PR Newswire)
Apr-24-24 11:43AM	Penumbra's (PEN) New Launch to Enhance Blood Clot Removal (Zacks)
Apr-23-24 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
09:00AM	Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots (PR Newswire)
Apr-09-24 04:05PM	Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024 (PR Newswire)
Apr-08-24 09:35AM	Here's Why You Should Retain Penumbra (PEN) Stock for Now (Zacks)
Apr-04-24 01:55AM	Insider Sell: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)
Mar-05-24 09:49AM	Penumbra (PEN) Gains From Innovation, Mounting Costs Ail (Zacks)
Feb-27-24 09:45AM	Why Penumbra (PEN) is a Top Growth Stock for the Long-Term (Zacks)
Feb-26-24 11:42AM	Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase (Zacks)
Feb-23-24 11:40AM	Q4 2023 Penumbra Inc Earnings Call (Thomson Reuters StreetEvents) -9.25%
10:44AM	Penumbra, Inc. (NYSE:PEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:11AM	Decoding Penumbra Inc (PEN): A Strategic SWOT Insight (GuruFocus.com)

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elsesser Adam	CEO and President	Mar 05 '25	Option Exercise	30.00	72,976	2,189,280	77,976	Mar 07 08:03 PM
Elsesser Adam	CEO and President	Mar 05 '25	Sale	283.59	61,600	17,468,917	16,376	Mar 07 08:03 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Mar 03 '25	Option Exercise	22.04	600	13,224	67,139	Mar 05 07:37 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Mar 03 '25	Sale	287.43	600	172,458	66,539	Mar 05 07:37 PM
O'Rourke Bridget	Director	Mar 03 '25	Sale	285.48	50	14,274	5,573	Mar 05 07:36 PM
Bose Arani	Director	Mar 03 '25	Sale	287.42	12,000	3,448,993	326,819	Mar 05 07:35 PM
Yuen Maggie	Chief Financial Officer	Mar 05 '25	Option Exercise	158.30	900	142,470	16,143	Mar 05 07:35 PM
Yuen Maggie	Chief Financial Officer	Mar 03 '25	Sale	286.00	2,000	571,995	15,243	Mar 05 07:35 PM
Shiu Lambert	Chief Accounting Officer	Mar 04 '25	Option Exercise	22.04	9,200	202,768	33,470	Mar 05 07:35 PM
Shiu Lambert	Chief Accounting Officer	Mar 03 '25	Sale	285.93	7,288	2,083,860	24,270	Mar 05 07:35 PM
Shiu Lambert	Chief Accounting Officer	Mar 04 '25	Sale	282.88	501	141,723	32,969	Mar 05 07:35 PM
ADAM ELSESSER	Officer	Mar 05 '25	Proposed Sale	283.59	61,600	17,468,975		Mar 05 04:27 PM
LAMBERT SHIU	Officer	Mar 04 '25	Proposed Sale	282.88	501	141,723		Mar 04 05:10 PM
Arani Bose	Affiliate	Mar 03 '25	Proposed Sale	285.44	48,000	13,701,120		Mar 03 04:47 PM
MAGGIE YUEN	Officer	Mar 03 '25	Proposed Sale	286.00	2,000	571,995		Mar 03 04:39 PM
LAMBERT SHIU	Officer	Mar 03 '25	Proposed Sale	285.93	7,288	2,083,853		Mar 03 04:36 PM
Johanna Roberts	Officer	Mar 03 '25	Proposed Sale	285.54	3,600	1,027,949		Mar 03 04:28 PM
Shiu Lambert	Chief Accounting Officer	Feb 14 '25	Option Exercise	22.04	4,525	99,731	29,503	Feb 19 07:39 PM
Grewal Harpreet	Director	Jan 03 '25	Sale	241.28	167	40,294	8,530	Jan 06 08:03 PM
Kassing Don W.	Director	Jan 02 '25	Sale	238.84	170	40,603	665	Jan 06 08:03 PM
Grewal Harpreet	Director	Jan 03 '25	Proposed Sale	241.28	167	40,294		Jan 03 03:50 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Dec 26 '24	Option Exercise	22.04	1,350	29,754	64,000	Dec 27 08:02 PM
Elsesser Adam	CEO and President	Dec 20 '24	Sale	242.96	15,000	3,644,438	837,582	Dec 23 07:37 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Dec 02 '24	Sale	244.49	600	146,697	63,444	Dec 03 08:27 PM
Shiu Lambert	Chief Accounting Officer	Dec 03 '24	Option Exercise	12.36	5,250	64,890	25,278	Dec 03 08:27 PM
Shiu Lambert	Chief Accounting Officer	Nov 29 '24	Sale	242.56	1,798	436,123	20,682	Dec 03 08:27 PM
Shiu Lambert	Chief Accounting Officer	Dec 02 '24	Sale	243.01	654	158,929	20,028	Dec 03 08:27 PM
LAMBERT SHIU	Officer	Dec 02 '24	Proposed Sale	243.01	654	158,929		Dec 02 04:05 PM
LAMBERT SHIU	Officer	Nov 29 '24	Proposed Sale	242.56	1,798	436,123		Nov 29 01:28 PM
Elsesser Adam	CEO and President	Nov 20 '24	Sale	237.28	15,000	3,559,176	852,582	Nov 22 08:38 PM
Adam Elsesser	Affiliate	Nov 20 '24	Proposed Sale	237.11	30,000	7,113,300		Nov 20 05:42 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Nov 18 '24	Sale	239.74	600	143,843	64,044	Nov 19 08:04 PM
Elsesser Adam	CEO and President	Oct 21 '24	Sale	204.56	15,000	3,068,367	867,582	Oct 23 07:31 PM
Grewal Harpreet	Director	Oct 02 '24	Sale	190.83	166	31,678	8,697	Oct 03 07:33 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Oct 01 '24	Sale	190.76	600	114,456	60,488	Oct 03 07:32 PM
Kassing Don W.	Director	Oct 01 '24	Sale	193.93	170	32,968	835	Oct 03 07:32 PM
Grewal Harpreet	Director	Oct 02 '24	Proposed Sale	190.83	166	31,678		Oct 02 04:00 PM
Elsesser Adam	CEO and President	Sep 20 '24	Sale	197.71	15,000	2,965,646	882,582	Sep 24 07:29 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Sep 03 '24	Sale	206.22	600	123,733	61,088	Sep 05 07:48 PM
Grewal Harpreet	Director	Sep 04 '24	Sale	204.11	782	159,614	8,863	Sep 05 07:48 PM
Grewal Harpreet	Director	Sep 04 '24	Proposed Sale	204.11	782	159,614		Sep 04 04:13 PM
Johanna Roberts	Officer	Sep 03 '24	Proposed Sale	202.32	2,400	485,568		Sep 03 07:02 PM
Elsesser Adam	CEO and President	Aug 23 '24	Sale	203.37	28,380	5,771,597	897,582	Aug 26 07:46 PM
Elsesser Adam	CEO and President	Aug 22 '24	Sale	200.00	1,620	324,000	925,962	Aug 26 07:46 PM
Adam Elsesser	Affiliate	Aug 22 '24	Proposed Sale	195.21	60,000	11,712,600		Aug 22 04:49 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Aug 13 '24	Sale	175.98	600	105,587	61,688	Aug 15 07:41 PM
Elsesser Adam	CEO and President	Jul 17 '24	Sale	202.52	15,000	3,037,744	927,582	Jul 19 07:31 PM
Kassing Don W.	Director	Jul 01 '24	Sale	179.99	170	30,598	1,005	Jul 03 08:02 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jul 01 '24	Sale	179.20	600	107,519	62,288	Jul 03 08:01 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jun 03 '24	Sale	188.90	600	113,339	62,888	Jun 05 07:31 PM
Elsesser Adam	CEO and President	May 20 '24	Sale	200.98	15,000	3,014,734	942,582	May 22 07:38 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	May 13 '24	Sale	207.41	600	124,447	63,488	May 15 07:34 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 01 '24	Sale	217.07	600	130,242	64,281	Apr 03 07:42 PM
Kassing Don W.	Director	Apr 01 '24	Sale	223.18	170	37,941	1,175	Apr 03 07:42 PM

Dollar change +0.01
Percentage change 0.03	%

Peers: BSX ABT MDT EW ISRG BIO JNJ IART LMAT ZBH

| Held by: VTI VB IWM VXF VBK IWO IHI VTWO SCHA VHT

Index	RUT	P/E	-	EPS (ttm)	-0.95	Insider Own	3.59%	Shs Outstand	48.87M	Perf Week	-9.79%
Market Cap	1.60B	Forward P/E	-	EPS next Y	-0.38	Insider Trans	-0.35%	Shs Float	47.12M	Perf Month	-21.22%
Income	-44.70M	PEG	-	EPS next Q	-0.22	Inst Own	96.02%	Short Float	3.02%	Perf Quarter	-3.65%
Sales	465.31M	P/S	3.44	EPS this Y	30.07%	Inst Trans	-5.59%	Short Ratio	2.54	Perf Half Y	21.70%
Book/sh	9.43	P/B	3.47	EPS next Y	42.15%	ROA	-7.31%	Short Interest	1.42M	Perf Year	-11.43%
Cash/sh	2.51	P/C	13.02	EPS next 5Y	53.58%	ROE	-9.64%	52W Range	18.94 - 43.11	Perf YTD	7.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.33%	ROI	-8.36%	52W High	-24.15%	Beta	1.64
Dividend TTM	-	Quick Ratio	2.62	Sales past 5Y	16.03%	Gross Margin	74.04%	52W Low	72.65%	ATR (14)	1.72
Dividend Ex-Date	-	Current Ratio	3.65	EPS Y/Y TTM	-44.89%	Oper. Margin	-6.02%	RSI (14)	29.73	Volatility	5.35% 4.88%
Employees	1300	Debt/Eq	0.17	Sales Y/Y TTM	16.55%	Profit Margin	-9.61%	Recom	1.00	Target Price	54.22
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	-56.74%	Payout	-	Rel Volume	0.53	Prev Close	32.69
Sales Surprise	2.50%	EPS Surprise	-63.12%	Sales Q/Q	16.64%	Earnings	Feb 12 AMC	Avg Volume	561.23K	Price	32.70
SMA20	-12.76%	SMA50	-13.11%	SMA200	9.21%	Trades		Volume	123,369	Change	0.03%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-24	Resumed	JP Morgan	Overweight	$40
Apr-23-24	Upgrade	Oppenheimer	Perform → Outperform	$32
Oct-23-23	Initiated	JMP Securities	Mkt Outperform	$60
Sep-29-23	Initiated	UBS	Buy	$56
Aug-05-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Reiterated	Needham	Buy	$53 → $63
Nov-06-20	Reiterated	Needham	Buy	$63 → $53
Apr-07-20	Initiated	Oppenheimer	Outperform	$45
Feb-06-20	Initiated	BTIG Research	Buy	$42
Jan-24-20	Reiterated	Needham	Buy	$39 → $48
Aug-13-19	Downgrade	Northland Capital	Outperform → Market Perform	$30
Apr-12-19	Initiated	JP Morgan	Overweight	$37
Oct-04-18	Reiterated	Needham	Buy	$36 → $39
Aug-02-18	Reiterated	Stifel	Buy	$32 → $34
Aug-02-18	Reiterated	Needham	Buy	$32 → $36
Jun-18-18	Reiterated	Needham	Buy	$26 → $32
Apr-27-18	Reiterated	Needham	Buy	$23 → $26
Jan-16-18	Reiterated	Needham	Buy	$25 → $23
Nov-02-17	Reiterated	Needham	Buy	$26 → $25
Jul-28-17	Reiterated	Needham	Buy	$25 → $26

Show Previous Ratings

Mar-12-25 08:00AM	AtriCure to Host Analyst & Investor Day on March 26, 2025 (Business Wire)
Feb-13-25 12:00PM	AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know (Zacks) -6.54%
10:29AM	Q4 2024 AtriCure Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	AtriCure Inc (ATRC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-12-25 05:30PM	Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings (Zacks)
05:15PM	Loading…
05:15PM	AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:38PM	AtriCure: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results (Business Wire)
Feb-11-25 09:15AM	Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-05-25 10:00AM	Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jan-23-25 06:26PM	Why AtriCure, Inc. (ATRC) Is Skyrocketing Now (Insider Monkey)
Jan-22-25 08:00AM	AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Jan-13-25 08:00AM	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst and Investor Day (Business Wire) +9.49%
08:00AM	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day (Business Wire)
Dec-23-24 08:00AM	AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
08:00AM	Loading…
Nov-20-24 08:00AM	AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-07-24 08:00AM	AtriCure to Participate in the Stifel 2024 Healthcare Conference (Business Wire)
Oct-30-24 10:19AM	Q3 2024 AtriCure Inc Earnings Call (Thomson Reuters StreetEvents) +18.35%
03:12AM	AtriCure Inc (ATRC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges (GuruFocus.com)
Oct-29-24 07:00PM	AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:10PM	AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:07PM	AtriCure: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-28-24 08:00AM	AtriCure to Participate in the UBS Global Healthcare Conference (Business Wire)
Oct-15-24 08:00AM	AtriCure Announces Launch of cryoSPHERE MAX Probe for Post-Operative Pain Management (Business Wire)
Oct-08-24 08:00AM	AtriCure to Announce Third Quarter 2024 Financial Results (Business Wire)
Oct-01-24 08:00AM	AtriCure Receives CE-Mark for the EnCompass Clamp (Business Wire)
Sep-18-24 10:43AM	Heres Why TimesSquare Capital U.S. Small Cap Growth Strategy Decided to Sell AtriCure (ATRC) (Insider Monkey)
Aug-28-24 06:32AM	AtriClip FLEX-Mini device treatment begins with first patient (Medical Device Network)
Aug-27-24 08:00AM	AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip FLEX-Mini Device (Business Wire)
12:07PM	Loading…
Aug-23-24 12:07PM	AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication (Zacks)
Aug-22-24 08:00AM	AtriCure Receives Expanded CE-Mark Indication for AtriClip Devices for the Reduction of Stroke in Patients with Atrial Fibrillation (Business Wire)
Jul-30-24 05:30PM	AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:09PM	AtriCure: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-29-24 08:00AM	AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference (Business Wire)
Jul-24-24 10:14AM	AtriCure (ATRC) Gains China Approval for AtriClip LAA System (Zacks)
Jul-23-24 08:00AM	AtriCure Receives Regulatory Approval to Sell AtriClip Devices in China (Business Wire)
Jul-09-24 08:00AM	AtriCure to Announce Second Quarter 2024 Financial Results (Business Wire)
Jun-28-24 06:50AM	Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 (InvestorPlace)
Jun-21-24 01:44AM	AtriCure (ATRC) Stock Slipped on Competition Threat (Insider Monkey)
May-31-24 07:00PM	Insider Buying: Chief Technical Officer Salvatore Privitera Acquires Shares of AtriCure Inc (ATRC) (GuruFocus.com)
May-15-24 08:00AM	AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference (Business Wire)
May-02-24 03:18PM	AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript (Insider Monkey) -10.26%
08:36AM	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating (MT Newswires)
03:49AM	AtriCure Inc (ATRC) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-01-24 08:57PM	ATRC Stock Earnings: AtriCure Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00PM	Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics (Zacks)
05:55PM	AtriCure Inc (ATRC) Surpasses Revenue Estimates in Q1 2024 Despite Wider Losses (GuruFocus.com)
05:30PM	AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:34PM	AtriCure: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 08:00AM	AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference (Business Wire)
Apr-23-24 07:07AM	--Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32 (MT Newswires)
Apr-19-24 09:45AM	AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management (Zacks)
Apr-18-24 08:00AM	AtriCure Announces Launch of the cryoSPHERE+ Probe for Post-Operative Pain Management (Business Wire)
Apr-10-24 08:00AM	AtriCure to Announce First Quarter 2024 Financial Results (Business Wire) -6.19%
Mar-26-24 08:00AM	AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-22-24 06:40AM	AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug (Insider Monkey)
Mar-07-24 09:01AM	Chief Legal Officer Karl Dahlquist Sells 8,231 Shares of AtriCure Inc (ATRC) (GuruFocus.com)
Feb-28-24 12:47AM	AtriCure (ATRC) Fell on Competitor Action (Insider Monkey)
Feb-16-24 11:30AM	AtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:24AM	Q4 2023 AtriCure Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-15-24 07:00PM	Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings (Zacks) +5.13%
05:10PM	AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:44PM	AtriCure Inc (ATRC) Reports Strong Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:15PM	AtriCure: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results (Business Wire)
Feb-12-24 09:16AM	Seeking Clues to AtriCure (ATRC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Jan-25-24 08:00AM	AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference (Business Wire)
Jan-08-24 08:00AM	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024 (Business Wire) +6.06%
Jan-04-24 08:00AM	AtriCure Appoints Shlomi Nachman to the Board of Directors (Business Wire)
Dec-20-23 08:00AM	AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-15-23 09:55AM	Wall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should Know (Zacks)
08:00AM	AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-14-23 08:00AM	AtriCure Releases 2023 ESG Report (Business Wire) +10.11%
Nov-06-23 12:00PM	All You Need to Know About AtriCure (ATRC) Rating Upgrade to Buy (Zacks)
Nov-02-23 03:14PM	AtriCure, Inc. (NASDAQ:ATRC) Q3 2023 Earnings Call Transcript (Insider Monkey)
09:23AM	Q3 2023 AtriCure Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 06:22PM	AtriCure Inc (ATRC) Reports Q3 2023 Earnings: 18.1% YoY Revenue Growth (GuruFocus.com)
06:00PM	AtriCure (ATRC) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
04:19PM	AtriCure: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-31-23 08:00AM	AtriCure to Participate in the Stifel 2023 Healthcare Conference (Business Wire)
Oct-11-23 08:00AM	AtriCure to Announce Third Quarter 2023 Financial Results (Business Wire) -5.28%
Sep-29-23 09:40AM	Brinker upgraded, Berkshire Hathaway downgraded: Wall Street's top analyst calls (The Fly)
Sep-11-23 11:45AM	Unveiling AtriCure (ATRC)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-09-23 07:32PM	Unveiling AtriCure (ATRC)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Jul-29-23 01:10AM	Insider Sell: AtriCure Inc's Chief Legal Officer Karl Dahlquist Sells 3,417 Shares (GuruFocus.com)
Jul-27-23 08:50AM	AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 63% Above Its Share Price (Simply Wall St.) -5.18%
Jul-26-23 07:49AM	Q2 2023 AtriCure Inc Earnings Call (Thomson Reuters StreetEvents) +8.54%
Jul-25-23 08:00PM	AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:15PM	AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:11PM	AtriCure: Q2 Earnings Snapshot (AP Finance)
04:01PM	AtriCure Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-21-23 08:00AM	AtriCure to Participate at Upcoming Investor Conferences (Business Wire)
Jul-03-23 08:00AM	AtriCure to Announce Second Quarter 2023 Financial Results (Business Wire)
May-25-23 04:02AM	UPDATE 1-Abu Dhabi makes its Falcon 40B AI model open source (Reuters)
May-04-23 06:21AM	AtriCure First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Prange Karen	Director	Mar 05 '25	Sale	38.12	6,100	232,532	17,828	Mar 07 08:21 AM
Prange Karen	Director	Mar 05 '25	Proposed Sale	38.04	6,100	232,044		Mar 05 10:02 AM
Yuen Maggie	Director	Aug 15 '24	Sale	24.07	3,500	84,245	8,970	Aug 19 08:46 AM
Yuen Maggie	Director	Aug 15 '24	Proposed Sale	24.07	3,500	84,245		Aug 15 08:06 PM
Privitera Salvatore	Chief Technical Officer	May 30 '24	Buy	22.25	5,000	111,250	103,290	May 31 04:12 PM
Noznesky Justin J	Chief Mktg & Strategy Officer	May 01 '24	Sale	24.09	1,500	36,135	71,284	May 03 08:51 AM
Noznesky Justin J	Chief Mktg & Strategy Officer	Apr 01 '24	Sale	30.39	1,500	45,585	72,784	Apr 03 08:41 AM
Dahlquist Karl S.	Chief Legal Officer	Mar 18 '24	Sale	32.16	1,885	60,622	50,954	Mar 20 08:41 AM

PEN

Penumbra Inc

ATRC

Atricure Inc

Upgrade your FINVIZ experience